AMBOSS, a leading resource for medical education and clinical decision-making in Germany and the US, closed a €240 million funding round with new long-term investors, supporting the exploration of additional international markets and the expansion of its offering to nurses and other health care professionals.
AMBOSS had recently converted to a European stock corporation (SE) and completed a financing round with new primary investors KIRKBI, M&G Investments and Lightrock with participation from existing shareholders.
Last year, AMBOSS acquired Novaheal, a start-up in the nursing field, and NEJM Knowledge+, a board exam prep product for residents in the US. The recent financing round significantly improves access to capital for AMBOSS.
AMBOSS heads the digital empowerment of physicians by keeping them at the center of the product so that they are tech-enabled to provide the best possible care. And doctors worldwide rely on AMBOSS to continuously combine the latest, trusted medical content with cutting-edge technology.
Over 1 million users in over 180 countries trust AMBOSS for clinical decision-making and medical education. And every second inpatient treatment in Germany is carried out by a physician supported by AMBOSS. In the US, the majority of medical students use AMBOSS to prepare for exams, and score higher than with other question banks. 25% of first-year US residents depend on AMBOSS to help them provide excellent patient care. The concept is as simple as it is successful: Medical experts distill relevant medical knowledge, and AI-supported technology places it directly at users’ fingertips.
Key to this success is strong in-house collaboration between experienced medical experts and technology specialists. Offering precise and actionable recommendations on diagnostics and treatment based on the latest guidelines, AMBOSS is a digital co-pilot for everyday clinical practice, helping to save time and avoid treatment errors.
Responsible use of AI technologies has long played a major role in the AMBOSS experience that so many educators and clinicians have valued and trusted for years. And AMBOSS will continue to lead the way through rigorous validation of outcomes and a value-first approach.
KEY QUOTES:
“We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond. Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.”
– Benedikt Hochkirchen, Co-Founder and Co-CEO of AMBOSS
“Technology will not replace health care professionals, but those who embrace it will lead the way.”
– Dr. Madjid Salimi, Co-Founder and Co-CEO of AMBOSS
“We have followed AMBOSS’ impressive growth journey, from its successful US expansion to its strong focus on innovation. Its unique platform is becoming a vital tool for both medical students and health care professionals, supporting learning and decision-making at every stage. We are excited to partner with other experienced technology and growth investors to back AMBOSS’ visionary leadership team in their mission of empowering the next generation of health care professionals worldwide.”
– Peter Bason, Head of Private Capital at KIRKBI
